91 results
8-K
EX-99.1
RVNC
Revance Therapeutics Inc
9 May 24
Revance Reports First Quarter 2024 Financial Results, Provides Corporate Update
4:08pm
will be focused on expanding our DAXXIFY and RHA customer base while also driving deeper account penetration. Overall, we are pleased with the traction we
8-K
EX-1.1
RVNC
Revance Therapeutics Inc
5 Mar 24
Other Events
5:08pm
, or customer or account number; (ii) Protected Health Information as defined by HIPAA; and (iii) “personal data” as defined by GDPR. The execution
424B5
RVNC
Revance Therapeutics Inc
5 Mar 24
Prospectus supplement for primary offering
5:00pm
they receive to their customers who are the beneficial owners, but only because they agree to do so in their customer agreements or because they are legally
424B5
jhsmwlujcd1b5vcok1uy
4 Mar 24
Prospectus supplement for primary offering
6:39am
8-K
EX-99.1
gd2dpxxf
28 Feb 24
Provides Corporate Update
4:07pm
8-K
EX-10.1
uoxqk8uh
13 Feb 24
Departure of Directors or Certain Officers
4:28pm
8-K
EX-99.1
s2znqz0hhp5l
8 Jan 24
Revance Provides Corporate Update, Preliminary Fourth Quarter and Full Year 2023 Financial Results, and Financial Outlook
8:01am
S-3ASR
mnbx w38nvc
14 Nov 23
Automatic shelf registration
4:22pm
8-K
EX-99.1
ttdep4wb4gwxytu1 zt
8 Nov 23
Provides Corporate Update
4:09pm
8-K
EX-99.2
1dihpz68z1yqbpmw5ixk
19 Sep 23
Revance Provides Corporate Update at Investor Day
9:01am
8-K
EX-1.1
glwi h829m1pcxj4r
13 Sep 22
Other Events
9:55pm
424B5
8mxrw
13 Sep 22
Prospectus supplement for primary offering
9:13pm